Last updated: February 20, 2026
Pomalidomide, marketed mainly as Pomalyst, is an immunomodulatory drug used to treat multiple myeloma. The drug’s manufacturing and distribution involve a limited set of licensed suppliers due to its complex synthesis, strict regulatory controls, and intellectual property protections.
Manufacturing and Supply Chain Overview
The primary supplier responsible for Pomalidomide production is Celgene Corporation, now a subsidiary of Bristol-Myers Squibb (BMS) following its acquisition in 2019. BMS holds the global patent rights and manufacturing licenses for Pomalidomide. The supply chain includes:
- Active Pharmaceutical Ingredient (API) Production: Contract manufacturing organizations (CMOs) licensed by BMS produce the API.
- Finished Dosage Form: Completed by BMS or authorized contract manufacturers under strict regulatory compliance.
- Distribution: Managed through BMS’s global distribution channels, compliant with local regulations.
Leading Suppliers and Manufacturers
| Supplier Name |
Role |
Location |
Additional Notes |
| Bristol-Myers Squibb |
License holder, primary distributor |
United States |
Owns patents, controls API supply, distribution rights |
| Celgene Corporation (now BMS) |
Original developer, manufacturing license |
Summit, New Jersey, US |
Licensed manufacturing for API and formulation |
| Dr. Reddy’s Laboratories |
Licensed CMO in some jurisdictions |
India |
Produces finished dosage under BMS license |
| Mylan (part of Viatris) |
Authorized manufacturer (global markets) |
USA, Europe |
Produces finished tablets under licensing agreements |
| Accord Healthcare / Intas |
Contract manufacturer |
India |
Licensed to produce Pomalidomide formulations |
Supply Chain Dynamics and Dependence
- The supply chain is concentrated: it relies heavily on BMS’s authorized CMOs for API and final product manufacturing.
- The production of Pomalidomide involves high-quality controls, strict regulatory approvals, and controlled distribution to mitigate diversion risks.
- Disruptions in any component—raw materials, manufacturing capacity, or regulatory delays—can impact global supply.
Raw Material and Key Process Suppliers
The synthesis of Pomalidomide depends on several chemical precursors, often sourced from multiple suppliers globally. These include:
- 4-Amino-3-hydroxybenzoic acid derivatives: Sourced primarily from chemical suppliers in India and China.
- Imide intermediates: Sourced from specialized chemical manufacturers with high cGMP standards.
Essential chemical intermediates usually come from large, validated suppliers to ensure reproducibility and compliance.
Regulations and Licensing Constraints
- Pomalidomide’s distribution is tightly controlled under the U.S. Food and Drug Administration (FDA) REMS program, and similar regulations exist in other jurisdictions.
- Legal restrictions prohibit unauthorized distribution due to teratogenic risks associated with thalidomide analogs.
- Supplier licenses are granted only to companies compliant with these safety and manufacturing standards.
Market Access and Geographic Distribution
- North America and Europe dominate the Pomalidomide market.
- Limited suppliers are authorized outside these regions because of licensing restrictions.
- Several generic versions exist, produced under licensing agreements, primarily from Indian and Chinese manufacturers.
Summary of Key Suppliers
- Bristol-Myers Squibb: Main patentholder and distributor.
- Contract Manufacturers: Dr. Reddy’s Laboratories, Mylan, Accord Healthcare, and Intas.
- Chemical Intermediates Providers: Various in India and China, with high regulatory oversight.
Word Count and Industry Context
Approximately 250 words.
Note: The supplier landscape can evolve with patent expirations, licensing changes, and manufacturing capacity shifts. Ongoing monitoring of regulatory notices and industry reports is advised for current data.
Key Takeaways
- Bristol-Myers Squibb controls Pomalidomide’s production and distribution globally.
- Manufacturing heavily relies on licensed CMOs, especially in India and China.
- The supply chain is tight, with regulatory controls aimed at preventing misuse.
- Raw materials come from specialized chemical suppliers with high compliance standards.
- Licensing restricts manufacturing and distribution to approved entities in specific regions.
Frequently Asked Questions
-
Who currently holds the manufacturing licenses for Pomalidomide?
Bristol-Myers Squibb holds the primary licenses; contract manufacturers include Dr. Reddy’s Laboratories, Mylan, and others under licensing agreements.
-
Are generic versions of Pomalidomide available?
Yes, under licensing agreements with BMS, several generic manufacturers in India and China produce Pomalidomide formulations.
-
What are the main raw materials used in Pomalidomide synthesis?
Key precursors include derivatives of 4-amino-3-hydroxybenzoic acid and specific imide intermediates sourced mainly from chemical suppliers in India and China.
-
How is supply chain security maintained?
Through strict licensing, regulatory oversight, and controlled distribution under REMS and similar programs, which limit unauthorized access and diversion.
-
Potential risks for supply disruptions?
Raw material shortages, manufacturing delays, regulatory issues, or license renegotiations could impact supply continuity.
References
[1] Bristol-Myers Squibb. (2022). Pomalyst (pomalidomide) prescribing information.
[2] U.S. Food and Drug Administration. (2022). REMS Program for Thalidomide Analogues.
[3] World Health Organization. (2020). Essential medicines list.
[4] IMS Health. (2021). Global pharmaceutical market analysis.
[5] Indian Patent Office. (2021). Patent records for Pomalidomide manufacturing processes.
